NICE
NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer
The drug was approved in the UK for previously treated patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.
UK's NICE Recommends Approval of Opdivo, Yervoy for MSI-High, MMR-Deficient Colorectal Cancer
The combination treatment has already been approved in the US and recommended for approval in this setting in Europe.
NICE Recommends Keytruda for Metastatic MSI-High, Mismatch Repair-Deficient Colorectal Cancer
The draft guidance recommends Merck's immunotherapy be available to patients in the UK with untreated MSI-high or dMMR colorectal cancer.
UK's MHRA Grants Early Access to AstraZeneca's Tagrisso as Adjuvant NSCLC Treatment
This is MHRA's first authorization under Project Orbis, an international regulatory collaboration the UK body joined in January to speed access to drugs.
NICE Recommends Enhertu for Advanced HER2-Positive Breast Cancer Through Cancer Drugs Fund
While more data are collected, Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan is available to pretreated, HER2-positive breast cancer patients in the UK.